#USA #Toronto #Specific Biologics #Dualase #Dr. Richard Glickman

Specific Biologics Welcomes Dr. Richard Glickman to Its Board

Specific Biologics Inc., a company dedicated to advancing precision in vivo genome editing, has officially appointed Dr. Richard Glickman to its Board of Directors. His extensive experience in the biotechnology sector, spanning over three decades, positions him as a valuable asset during this critical phase of the company’s development.

Dr. Glickman's Impressive Background

Dr. Glickman is no stranger to the biotech landscape, having co-founded and led several notable organizations. His entrepreneurial ventures include StressGen Biotechnologies, Aspreva Pharmaceuticals, and Aurinia Pharmaceuticals, showcasing his ability to guide companies from concept through to commercialization. Notably, he played a pivotal role in the acquisition of Aspreva Pharmaceuticals for an impressive $915 million, highlighting his skill in navigating complex drug development and corporate strategy problems.

In addition to his leadership in company development, Dr. Glickman has served on various boards of both public and private biotechnology firms. His past chair positions at companies such as Aurinia Pharmaceuticals and ESSA Pharma underscore his ability to scale emerging biopharma entities and enhance their competitive presence in global markets. Moreover, his commitment to patient advocacy and community health has earned him accolades from prestigious organizations like the Lupus Foundation of America, among others.

Strategic Importance for Specific Biologics

Paul J. Hastings, Chair of the Board at Specific Biologics, expressed great enthusiasm about Dr. Glickman’s appointment, recognizing his expertise in building successful biotech firms, forging global partnerships, and steering platform technologies towards commercial success. “We are thrilled to welcome Dr. Glickman to the Board at this pivotal stage for Specific Biologics,” Hastings stated, indicating the strategic advantage Glickman’s insights will bring.

Responding to his new role, Dr. Glickman shared his excitement regarding Specific Biologics' cutting-edge advancements in genome editing. He emphasized the potential of the company's Dualase® genome editors to address severe genetic disorders like amyotrophic lateral sclerosis (ALS), where effective therapeutic options are urgently needed. His focus on delivering durable, gene-level benefits reflects a commitment to innovative solutions in genetic disease treatment.

Transition and Leadership Growth

As Dr. Glickman joins the board, Specific Biologics also announces that Frédéric Lemaître Auger will be stepping down after invaluable contributions to the company’s strategy and governance. CEO Brent Stead expressed gratitude for Dr. Lemaître Auger’s impact on the foundation of Specific Biologics, acknowledging his guidance as instrumental in positioning the company for future expansion.

Specific Biologics is dedicated to enhancing its governance and leadership team as part of its ongoing commitment to advancing its differentiated therapeutics. The company is known for its robust Dualase® platform, which uniquely enables precise interventions across a variety of genetic diseases through a best-in-class accurate editing mechanism.

About Specific Biologics

Specific Biologics is a biotechnology firm recognized for its work in creating the Dualase® platform, renowned for its high-efficiency and programmable in vivo genome editing capabilities. By focusing on the urgent therapeutic needs posed by genetic diseases, the company endeavors to utilize its advanced techniques to change the treatment landscape for patients worldwide. With a focus on delivering groundbreaking therapies, Specific Biologics aims to bridge the gap in treatments available for numerous conditions, leveraging cutting-edge genetic engineering technology.

For further details, visit Specific Biologics or follow them on LinkedIn.